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Loss of heterozygosity (LOH) on chromosome 17q21 has been detected in 30% of primary human breast tumours. The smallest
common region deleted occurred in an interval between the D17S746 and D17S846 polymorphic sequences tagged sites that are
located on two recombinant P1-bacteriophage clones of chromosome 17q21: 122F4 and 50H1, respectively. To identify the target
gene for LOH, we defined a map of this chromosomal region. We found the following genes: JUP, FK506BP10, SC65, Gastrin (GAS)
and HAP1. Of the genes that have been identified in this study, only JUP is located between D17S746 and D17S846. This was of
interest since earlier studies have shown that JUP expression is altered in breast, lung and thyroid tumours as well as cell lines having
LOH in chromosome 17q21. However, no mutations were detected in JUP using single-strand conformation polymorphism analysis
of primary breast tumour DNAs having LOH at 17q21. We could find no evidence that the transcription promoter for JUP is
methylated in tumour DNAs having LOH at 17q21. We suspect that the target gene for LOH in primary human breast tumours on
chromosome 17q21 is either JUP and results in a haploinsufficiency for expression or may be an unidentified gene located in the
interval between D17S846 and JUP.
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We (Cropp et al, 1993; Cropp et al, 1994), and others (reviewed in
(Bieche et al, 1997; Osborne and Hamshere, 2000), have shown that
sporadic human breast carcinomas are characterised by the
frequent loss of heterozygosity (LOH) on chromosome 17q12–
21. A common speculation of these studies, based on Knudson’s
work (Knudson, 1971), is that LOH reveals a recessive somatic
mutation in a gene, designated a tumour suppressor gene, within
the other unaffected homologous chromosome. We have defined a
region, using 17 polymorphic sequences tagged sites (STS), on
human chromosome 17q21 that is affected by LOH in 30% of 130
sporadic breast tumours spanning the region between D17S746 to
D17S846 (Cropp et al, 1994). Two P1-bacteriophage clones, 122F4
and 50H1, of human genomic DNA were identified that contain
D17S746 and D17S846, respectively (Albertsen et al, 1994 and
unpublished data). We have determined, partially, the nucleotide
sequence of 122F4 and 50H1 as a strategy to identify candidate
genes that could be targets for mutation in breast tumour DNAs
having LOH in this region of chromosome 17q21. In the present
communication, we identify six genes that are located on
chromosome 17q21, their relative gene order and their transcrip-
tional orientation. This study compliments the Draft Human
Genome Nucleotide Sequence in that it physically locates the
Plakoglobin (JUP) gene between the two polymorphic markers,
D17S746 and D17S846, previously used to identify the smallest
common region of LOH in sporadic breast cancer (Cropp et al,
1994). Analysis of breast tumour DNAs having LOH at 17q21
revealed no mutations in JUP, SC65, FK506BP10 and MGC20781
genes that are expressed in normal breast epithelium. JUP has also
been screened for methylation of its transcription promoter
regions to determine if an epigenetic mechanism could affect the
expression of the remaining allele such as that found for FHIT in
breast tumours (Yang et al, 2002). No methylation has been found
in the series of 10 sporadic breast tumour DNAs having LOH at
chromosome 17q12–q21.
MATERIALS AND METHODS
Characterisation of 17q12–21
Two P1 phages clones were used to analyse the 17q12–q21 region:
122F4 and 50H1 (generously provided by Dr Ray White,
Department of Oncological Sciences, Huntsman Cancer Institute,
University of Utah, Salt Lake City, UT, USA). Libraries of 122F4
and 50H1 were constructed using standard techniques with BamHI
or SSTI genomic restriction fragments, respectively, cloned into
the pBluescript II KS (þ) vector (Stratagene, La Jolla, CA, USA)
(Miyazaki et al, 1999). Subclones were subsequently ordered by
size, restriction enzyme and nucleotide end-sequence analysis
using universal primers from the vector. Nucleotide sequence
analysis was performed using the ABI Big Dye Terminator
sequencing kit (PE Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions on an ABI 377
automated sequencer from PE Applied Biosystems (Foster City,
CA, USA). The alignment of nucleotide sequences was determined
with the Sequence Analysis Software Package by Genetics
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sComputer Group (GCG), Inc. (Smithies et al, 1981). Within the
GCG package fragment assembly was performed by the fragment
assembly system based on the method of Staden (1980).
Comparison of different sets of nucleotide sequences was analysed
by the Best-Fit sequence alignment program (Needleman and
Wunsch, 1970; Smith and Waterman, 1981). The genomic
sequences obtained were compared using BLAST query with the
GenBank. Colony hybridisation (Miyazaki et al, 1999) was used to
identify additional clones of overlapping or adjacent restriction
fragments that contained particular genes or exons of genes.
Probes for colony hybridisation were cDNA clones for: the mouse
homologue of FK506BP10 (generously provided by Dr Stephanie L
Simek, Science Applications International Corp., NCI-Frederick
Cancer Research and Development Center, MD, USA) (Coss et al,
1995), human JUP (pHPG Ca 2.1, generously provided by Dr
Werner W Franke, German Cancer Research Center, Heidelberg,
Germany) (Franke et al, 1989) and human EST clones (Research
Genetics, Huntsville, AL, USA) for SC65 and MGC20781. Each
probe was labelled with [a-
32P]dCTP by random priming
(Rediprime II kit, Amersham, Piscataway, NJ, USA).
Reverse trancriptase–polymerase chain reaction
(RT–PCR) analysis
For JUP expression, an RT–PCR assay was performed, using a
Superscript One-Step RT-PCR kit with Platinum Taq Polymerase
from Invitrogen (Carlsbad, CA, USA). Normal tissue total
RNA (10ng), purchased from Clontech, was used as template.
The JUP primers for Exon 1A were: forward, 50-CCGAGCT-
CAGTTCGCTGT-30; reverse, 50-TCGTTGAGC AGTTTGGTGAG-30;
for Exon 1B were: forward, 50-ACCCGCT TTCCTGAAAGAAT-30;
reverse, 50-AGCAGAAGCGAGA\CTG TCCT-30. The GAPDH pri-
mers were used as a control for the amount of RNA tested:
forward, 50-CCCTTCATTGACCTCAACTAC-30; reverse, 50-
CCACCTTCTTGATGTCATCAT-30 to amplify a 600 base pair
(bp) fragment. A measure of 25mlo f2   mixture containing
0.4mM of each dNTP, 2.4mM MgSO4,1 0mM of each primer, 1mlo f
Rt/Platinum Taq mix and autoclaved (RNAse-free) distilled water
up to 50ml of total reaction volume. The cDNA synthesis and
predenaturation was performed at 521C for 30min for one cycle
and the PCR amplification was performed for 35 cycles at 941C for
15s, 521C for 30s and 721C for 1min. A final extension was
performed at 721C for 10min.
Mutation screening
‘Cold’ single-strand conformation polymorphism (SSCP) analysis
was performed as described by Hongyo et al (1993) to identify
mutations in JUP genomic from breast tumours having LOH on
chromosome 17q21. The primers used correspond to intron
sequences located 50 and 30 of the particular exon (Table 1). After
an initial denaturation cycle of 941C for 5min, amplification from
100ng genomic DNA was carried out with two cycles each of (941C
10min, 661C 10min, 721C 20min), (941C 10min, 641C 10min,
721C 20min), (941C 10min, 621C 10min, 721C 20min), (941C
10min, 601C 10min, 721C 20min) and then 25 cycles of (941C
10min, 561C 10min, 721C 20min) with a final extension cycle at
721C for 7min. All SSCP products were analysed on 4–20% precast
polyacrylamide gels (Novex, San Diego, CA, USA) in TBE at 325V
for 60min at a primer set-dependent temperature (see Table 1)
using the manufacture’s conditions. The gels were stained with
SYBR Green II (Molecular Probes, Inc., Eugene, OR, USA) using
the manufacture’s conditions, visualised using a 340nm UV
viewing box and photographed.
Methylation-specific PCR for the JUP transcription
promoter
As a positive control for CpG methylation of genomic DNA, we
have methylated a restriction fragment of recombinant genomic
DNA containing the JUP transcription promoter. This was
performed using the SssI methylase (CpG methylase) (New
England Biolabs, Inc., Beverly, MA, USA) and the manufacturer’s
conditions. A PCR-based experimental protocol was used to detect
hypermethylation of genomic DNA (Herman et al, 1996; Dracopoli
et al, 1998). Briefly, 1mg of primary breast tumour genomic or
control recombinant DNA containing the JUP promoter was
treated with sodium bisulphite. Modified and nonmodified control
and tumour DNA were used as templates in PCR reactions with
FastStart Taq DNA Polymerase (Roche Molecular Biochemicals,
Indianapolis, IN, USA). The reaction mixture contained 5mlo f
10 PCR buffer (containing 2mM MgCl2), 1mlo f1 0 m M PCR
Nucleotide Mix, 250ng of each primer, 0.4ml FastStart Taq DNA
Polymerase (2U), 1ml of bisulphite modified DNA and distilled
water to 50ml total volume. The primer pairs for unmethylated
DNA: PgU F, forward 50-TTGGAGTAGTTGTTGTTTGATTGT-
GTT-30; PgUR reverse 50-CAAACCAAATCAAAATCAAACCAA-30;
and for methylated DNA: PgMeth F forward 50-TAGTCGTCGTTC-
GATCGCGTC-30; PgMethR reverse 50-AACCGAATCGAAATC-
GAACCG-30 have been previously described by Potter et al
(2001) and lead to the amplification of 84 and 76bp fragments,
respectively. The PCR reactions were placed in an Applied
Biosystems GeneAmp PCR System 9700 thermal cycler and
activated at 951C for 4min, denatured at 951C for 30s, annealed
at 561C for 30s and elongated at 721C for 1min for 35 cycles. A
final extension of 721C for 7min and a 41C indefinite hold
Table 1 Primers for the amplification of JUP exons
Exon Intron location
a Forward (50–30) Intron location
b Reverse (50–30) Gel running temp. (C1)
c Product (bp)
d
1  16 ATACTCAGTAGCCACGAT +13 CCCCATGCAATAGTCCC 15 254
2  15 CTGCACTCAGTCCCTGTC +6 ACCCTGCAGGGACCCTC 15 315
3  1 CTGCCTTTGCCCTCCAG +6 AACCCTGCTCACTGCATG 15 279
4  6 GTACTAACCCCTGCCCAC +13 TCAGGCCTCGGGAGAGTT 12 255
5  4 CTCATTCCCTCTTTACCC +3 CCCTCAAGGCCATCATACT 15 188
6  8 TGATGGCACCCCTATCCC +11 CAACCCCAGGCCCAGAT 15 157
7  24 TTGGCTGCTCCCTGACTC +22 CTGCTGCAGGGAGCTCCT 15 420
8  9 ACTGCCCCTTTTTTTGCC +175 GCATGGGACAGGTGCCTT 17–18 350
9  22 AAGGCACCTGTCCCATGC +53 TCTGGGACTCCTAACCTT 17–18 230
10  12 TCCCCTGCTTCCCACGTC +55 TTAAACGTCGGCCAGCC 12–13 249
11  4 CCTGGCTTTTCCTTTCCTCTCT +10 ACTACTGTGGTCCAACCT 15 178
12  51 ACCAGCTGAGATCCAGCT +16 TCTCCAGGGTCCTGAAGA 12–13 143
13  20 TGCAGACCCTAGGACCGA +43 GGAAAAGCCTCAAAGA 15 232
aThe forward primer for Exon1 starts 16bp 50 to the translation start signal, for the other Exons the number given is the base pair separating the last base of the primer and the
begining of the Exon.
bThe number given is the base pair separating the last base of the Exon and the 30 end of the reverse primer.
cThe temperature at which the 4–20%
polyacrylamide gel was run.
dThe size of the PCR product is indicated base pairs.
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scompleted the reaction. For analysis, 12ml of each PCR reaction
was mixed with 5 Hi-Density TBE sample Buffer (Invitrogen,
Carlsbad, CA, USA) and loaded onto a 6% TBE Gel (Invitrogen).
The gel was run at 200V for 30min, stained with ethidium
bromide and visualised on a UV light box.
RESULTS AND DISCUSSION
To identify new genes with a potential tumour suppressor function
and determine their position within the region of chromosome
17q12–21 affected by LOH, we have determined the nucleotide
sequence of portions of the 122F4 and 50H1 P1-phage clones of
human genomic DNA that span the region between the D17S846
(centromeric) and D17S746 (telomeric) polymorphic markers
(Figure 1). Nucleotide sequence analysis of BamHI and SSTI
fragments of 122F4 demonstrated the presence of the JUP
gene. Previous studies (Aberle et al, 1995; Whittock et al, 2000)
localised JUP within this area of chromosome 17. In the present
study, we can now physically link JUP to SC65 (Exons 1–8),
FK506BP10 (Exons 1–10) and MGC20781 (Exon 8). FK506BP10 is
a member of a family of genes that encode proteins that are
immunophilins that bind FK506 and rifampysin and possess
prolyl:prolyl isomerase activity (Siekierka et al, 1989; Standaert
et al, 1990). The normal function of Fk506BP10-, SC65- and
MGC20781-encoded proteins is not known. Only the last exon
(Exon 8) of MGC20781 is located on 122F4. The results of a PCR
analysis of the exons for each of these genes on 122F4 are shown in
Figure 1A.
We have also localised by PCR analysis D17S746 and D17S846
on these P1-phage clones (Figure 1B). D17S846 is located B7.8kb
from one end of the recombinant genomic DNA in P1-phage 50H1
and is 2291bp from the transcription promoter region of HAP1.
The D17S746 locus is present on 122F4 but not on 50H1,
suggesting that it is located near JUP. This observation was
confirmed by nucleotide sequence analysis of a recombinant clone
from a library of SSTI-digested 122F4 DNA. D17S746 is located
3865bp telomeric of JUP Exon 1A (Figure 1B). The HUM122F4-30
Figure 1 (A) A partial map of human chromosome 17q12–q21. The PCR products of an analysis of the P1-phage clones are shown for the presence of
exons corresponding to the indicated genes. The arabic numbers represent the templates used to perform the PCR amplification of the indicated exon: lane
1, water control; lane 2, 122F4; lane 3, 50H1 P1-phage clones; lane 4, genomic DNA control. The intron/exon primers of all the genes are available upon
request. The sizes of the PCR-amplified fragments are indicated in bp. The arrow indicates transcriptional orientation 50–30 of the indicated genes. The
portions of the map with right-hand hatch marks correspond to regions in which the nucleotide sequence of the exon/intron junctions was determined. The
regions of the map in which the entire nucleotide sequence was determined are indicated with left-hand hatch marks. The centromeric end of the map is on
the left and the telomeric end is on the right side. (B) A map of the region of chromosome 17q12–q21 affected by LOH. The positions of Exons 1A, 1B, the
remainder of JUP exons and HAP1 as well as D17S846, 122F4-30 and D17S746 on the chromosome map are indicated. The PCR products of an analysis of
the P1-phage clones, 50H1 and 122F4, are shown for the presence of D17S846, HUM122F4-30 (accession number L32940) and D17S746. The arabic
numbers represent the templates used to perform the PCR amplification of the indicated exon: lane 1, water control; lane 2, 122F4; lane 3, 50H1 P1-phage
clones; lane 4, genomic DNA control. The regions of the map in which the entire nucleotide sequence was determined are indicated with left-hand hatch
marks.
Plakoglobin and loss of heterozygosity on chromosome 17q21
L DeMarchis et al
2386
British Journal of Cancer (2004) 90(12), 2384–2389 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sSTS locus is located 191bp from one end of the genomic fragment
in the 122F4 P1-phage clone.
The transcriptional orientation of the genes could be deduced by
PCR and nucleotide sequence analysis. Thus of the genes on 122F4,
JUP Exon 13 is located B11.5kb from the HUM122F4-30 STS locus
(Figure 1). This is consistent with the direction of transcription
being from the telomeric to centromeric regions of the chromo-
some. This analysis was also anchored with the observation that
only Exon 8 of MGC20781 was found on 122F4 and is consistent
with the transcriptional orientation of this gene being in the same
direction as JUP (Figure 1). In addition, Exon 8 of MGC20781
could be linked to a 3.4kb PCR fragment containing Exon 10 of
FK506BP10, which is consistent with the transcriptional orienta-
tion of FK506BP10 being in the opposite direction as JUP.
Similarly, Exon 8 of SC65 and D17S746 were linked in an 11kb
PCR fragment (Figure 1) consistent with the transcriptional
orientation of SC65 as being in the same direction as JUP. These
results confirm the Human Genome Map and physically locate the
STS loci HUM122F4-30 and D17S746, respectively.
As genes were identified in this study, we screened genomic
DNA from 11 primary human tumours having LOH in this region
of chromosome 17 by nucleotide sequence analysis. No missense,
nonsense or frameshift mutations were detected in SC65,
FK506BP10 or MGC20781 in these tumours DNAs. Gastrin (GAS)
and HAP1 were not tested since they are not expressed in the
mammary gland. When it was clear that among the genes that were
analysed, only JUP was located between D17S746 and D17S846;
JUP genomic DNA was tested by the more sensitive ‘cold’ SSCP
analysis (Osborne et al, 1991; Hongyo et al, 1993) for mutations,
none were found (data not shown).
JUP has two potential transcription promoters. JUP, Exon 1A
was expressed in 10 tissues tested (Figure 2), whereas Exon 1B
could not be detected in any of these tissues (Figure 2). However,
five ESTs that contain Exon 1B from a placenta cDNA library
(NIH_MGC_21) have been reported in the GenBank. One of these
is the positive control shown in Figure 2B (lane 12).
Winn et al (2002) demonstrated that plakoglobin expression is
reduced or absent in a subset of human lung cancers. Further they
showed that re-expression of plakoglobin inhibits transformed cell
growth, suggesting JUP is a tumour suppressor gene. Blanco et al
(2002) found that 76% (13 out of 17) invasive ductal carcinomas of
the breast had reduced levels of plakoglobin. Potter et al (2001)
have shown that in some thyroid tumours and cell lines, which
express low or undetectable levels of plakoglobin, the JUP
promoter is hypermethylated. To see if a similar phenomenon
affects the remaining JUP allele in breast tumours having LOH at
chromosome 17q21, we have examined the methylation status of
the transcription promoter region for JUP. The specificity of the
primers for methylated and unmethylated JUP Exon 1A is shown
in Figure 3A. No PCR product (Figure 3B, lanes 2–12) the size of
the control fragment (lane 13) of methylated JUP Exon 1A was
detected using the tumour DNAs as the template. However, as
shown in Figure 3C, lanes 2–12, PCR products of the same size as
the control (lane 13) for unmethylated DNA was detected with
tumour DNA templates. JUP Exon 1B was not tested for its
12 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 A
B
C
Figure 2 An RT–PCR assay of JUP Exon 1A (A), Exon 1B (B) and
GAPDH (C) RNA expression. Lane 1 is Marker HaeIII-digested phi X174
DNA. RT–PCR was performed on RNA from: lane 2, heart; lane 3, kidney;
lane 4, peripheral blood lymphocytes; lane 5, liver; lane 6, placenta; lane 7,
lung; lane 8, muscle; lane 9, ovary; lane 10, mammary gland; lane 11, small
intestine; lane 12, EST-395811 cDNA containing Exon 1B; lane 13, pHPG
Ca 2.1 cDNA containing Exon 1A; lane 14, water.
12 3 4 5
bp
118
118
118
72
72
72
1 2 3 4 5 6 7 8 91 01 1 1 21 3 1 4
A
B
C
Figure 3 Methylation-specific PCR of the JUP promoter region in
primary breast tumour DNAs having LOH on chromosome 17q21. (A)
Test of primer pairs for PCR of unmethylated and in vitro methylated
recombinant genomic DNA containing the JUP promoter region: lane 1,
Marker HaeIII-digested phi X174 DNA; lane 2, methylated-specifc primers
and methylated JUP genomic DNA; lane 3, methylated specifc primers and
unmethylated JUP genomic DNA; lane 4, unmethylated specifc primers and
methylated JUP genomic DNA; lane 5, unmethylated specifc primers and
unmethylated JUP genomic DNA. PCR analysis of primary breast tumour
DNAs with methylation specific primers (B) or primers specific for
unmethylated JUP genomic DNA (C). The DNAs were: lane1, Marker
HaeIII-digested phi X174 DNA; lane 2, tumour 16; lane 3, tumour 20; lane
4, tumour 26; lane 5, tumour30; lane 6, tumour 44; lane 7, tumour 62; lane
8, tumour 63; lane 9, tumour 89; lane 10, tumour 117; lane 11, tumour127;
lane 12, unrelated genomic DNA; lane 13, control methylated recombinant
JUP promoter region (B) and control unmethylated recombinant JUP
promoter region (C); lane 14, water control.
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smethylation status since it is not active in the mammary gland
(Figure 2).
In conclusion, we have focused on 122F4 and 50H1 P1-phage
clones because they contain (Albertsen et al, 1994, and unpub-
lished data) overlapping genomic DNA fragments that spanned a
region of chromosome 17q21 affected by LOH. Our nucleotide
sequence analysis of the ends of the genomic DNA in these P1-
phage clones is consistent with an overlap of 2.3kb. At the present
time, this region of chromosome 17q12–q21 is ambiguous with
respect to the presence and location of particular genes identified
in the Human Genome Project. For instance, D17S746 has not been
physically mapped relative to JUP in the Human Genome Project
map. However, consistent with our data, Aberle et al (1995), have
identified three recombinant cosmid clones of this region of
human chromosome 17q21 that contained both D17S846 and JUP.
It is possible, therefore, that the target gene for LOH on
chromosome 17q21, in primary human breast tumours, could be
located in the intervening nucleotide sequences between D17S846
and JUP (17489bp, GenBank). At the present time, however, there
is no evidence for a gene in this region of chromosome 17q21 in
the Human Genome Project map.
Another possibility is that JUP is the target for LOH. JUP
encodes g-catenin or plakglobin and is highly homologous to
b-catenin (Gumbiner, 1996). Both are components of cell–cell
adherens junctions linking cadherin receptors to the actin
cytoskeleton (Ben-Ze’ev and Geiger, 1998). In addition,
plakoglobin is a component of desmosomes (Franke et al,
1989; Ben-Ze’ev and Geiger, 1998). Immunohistochemical
analysis of primary human breast tumours for the expression
of the catenin family demonstrated that if one of these proteins
is downregulated, the function of the others in suppressing
metastasis is altered (Bukholm et al, 1998; Gonzalez et al, 1999).
In another study, it was shown that expression of plakoglobin
was selectively downregulated in metastatic tumours (Bukholm
et al, 2000). We have found no evidence that in tumours
having LOH between D17S846 and D17S746 the remaining
allele of JUP is mutated. Nor have we found evidence that the
transcription promoter of JUP is methylated preventing transcrip-
tion of the remaining allele in these tumours. Therefore, we
speculate that haploinsufficiency of JUP caused by LOH is
sufficient to contribute to breast tumour progression. A
future study specifically aimed at correlating LOH of JUP and
reduced plakoglobin levels in primary breast tumours seems
warranted.
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